Abstract
Purpose
The aim of this study was to determine to what extent we could identify the metabolism product peak using 3-T proton magnetic resonance spectroscopic imaging (MRSI) of the prostate gland in healthy volunteers by combining an external array coil with Malcolm Levitt composite-pulse decoupling sequence (MLEV)-point-resolved spatially localized spectroscopy (PRESS).
Materials and methods
MRSI data were obtained from the entire prostate gland in six healthy volunteers. The heights of the choline, citrate peaks and the standard deviation (SD) of the noise in each voxel were calculated. When the choline and/or citrate peak in a voxel exceeded 3 SD, the peak was clearly identified.
Results
The clear citrate peak rate in the peripheral zone (PZ) and the central gland (CG) were 78.8 and 70.3 %, respectively. The clear choline peak rate in the PZ and the CG were 55.4 and 44.9 %, respectively. In addition, the clear peak rates for both citrate and choline in the PZ and the CG were 51.8 and 38.6 %. Therefore, in the entire prostate gland, 75.2 % had a clear citrate peak, 51.1 % had a clear choline peak, and 46.3 % had both citrate and choline peaks.
Conclusion
The citrate peak was clearly detected in 75.2 % of the voxels by this technique.
References
Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Radiology. 1996;198:795–805.
Weinreb JC, Blume JD, Coakley FV, Wheeler TM, Cormack JB, Sotto CK, et al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy—results of ACRIN prospective multi-institutional clinicopathologic study. Radiology. 2009;251:122–33.
Heerschap A, Jager GJ, van der Graaf M, Barentsz JO, de la Rosette JJ, Oosterhof GO, et al. In vivo proton MR spectroscopy reveals altered metabolite content in malignant prostate tissue. Anticancer Res. 1997;17:1455–60.
Kurhanewicz J, Vigneron DB, Nelson SJ, Hricak H, MacDonald JM, Konety B, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology. 1995;45:459–66.
Lichy MP, Pintaske J, Kottke R, Machann J, Anastasiadis A, Roell S, et al. 3D proton MR spectroscopic imaging of prostate cancer using a standard spine coil at 1.5 T in clinical routine: a feasibility study. Eur Radiol. 2005;15:653–60.
Brown MA. Time-domain combination of MR spectroscopy data acquired using phased-array coils. Magn Reson Med. 2004;52:1207–13.
Kaji Y, Wada A, Imaoka I, Matsuo M, Terachi T, Kobashi Y, et al. Proton two-dimensional chemical shift imaging for evaluation of prostate cancer: external surface coil vs. endorectal surface coil. J Magn Reson Imaging. 2002;16:697–706.
Yakar D, Heijmink SW, Hulsbergen-van de Kaa CA, Huisman H, Barentsz JO, Fütterer JJ, et al. Initial results of 3-dimensional 1H-magnetic resonance spectroscopic imaging in the localization of prostate cancer at 3 Tesla: should we use an endorectal coil? Investig Radiol. 2011;46:301–6.
Scheenen TW, Heijmink SW, Roell SA, Hulsbergen-Van de Kaa CA, Knipscheer BC, Witjes JA, et al. Three-dimensional proton MR spectroscopy of human prostate at 3 T without endorectal coil: feasibility. Radiology. 2007;245:507–16.
Bottomley PA. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci. 1987;508:333–48.
Scheenen TW, Gambarota G, Weiland E, Klomp DW, Fütterer JJ, Barentsz JO, et al. Optimal timing for in vivo (1)H-MR spectroscopic imaging of the human prostate at 3T. Magn Reson Med. 2005;53:1268–74.
Scheenen TW, Klomp DW, Roll SA, Fütterer JJ, Barentsz JO, Heerschap A. Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate. Magn Reson Med. 2004;52:80–8.
Futterer JJ, Scheenen TW, Huisman HJ, Klomp DW, van Dorsten FA, Hulsbergen-van de Kaa CA, et al. Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Investig Radiol. 2004;39:671–80.
Cunningham CH, Vigneron DB, Marjanska M, Chen AP, Xu D, Hurd RE, et al. Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T. Magn Reson Med. 2005;53:1033–9.
Wilman AH, Allen PS. The response of the strongly coupled AB system of citrate to typical 1H MRS localization sequences. J Magn Reson B. 1995;107:25–33.
van der Graff M, Jager GJ, Heerschap A. Removal of the outer lines of the citrate multiplet in proton magnetic resonance spectra of the prostatic gland by accurate timing of a point-resolved spectroscopy pulse sequence. MAGMA. 1997;5:1–5.
Schricker AA, Pauly JM, Kurhanewicz J, Swanson MG, Vigneron DB. Dualband spectral–spatial RF pulses for prostate MR spectroscopic imaging. Magn Reson Med. 2001;46:1079–87.
Costello LC, Franklin RB. Concepts of citrate production and secretion by prostate. 1. Metabolic relationships. Prostate. 1991;18:25–46.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yoshizako, T., Uchida, K., Hara, S. et al. Prostate 3T-MR spectroscopic imaging without an endorectal surface coil using the MLEV-PRESS sequence. Jpn J Radiol 31, 220–225 (2013). https://doi.org/10.1007/s11604-012-0165-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11604-012-0165-5